---
title: Oral anticoagulation-atrial fibrillation
---

# Oral anticoagulation-atrial fibrillation

(Circ 2014;130:e199 & 2019;140:125; EHJ 2021;42:373)

- All valvular AF because stroke risk very high
- Nonvalvular AF (NVAF): stroke risk ~4.5%/y but varies; a/c → 68% ↓ stroke but ↑ bleeding
- [[CHA2DS2-VASc]] to guide Rx:

## Score Points

- score >=2 in ♂ or >=3 in ♀→ anticoagulate;
- scores 1 in ♂ or 2 in ♀ → consider anticoag or ASA or no Rx;
- score 0 → reasonable to not Rx

## Treatment options

- Rx options: DOAC (NVAF only) _prefered over warfarin_ (INR 2–3);
- if Pt refuses anticoag, ASA + clopi or, even less effective, ASA alone (NEJM 2009;360:2066)
- AF + CAD/ PCI:
  - consider DOAC + clopi (not ticag or prasugrel) + ASA (d/c ~1–4 wks) (Circ 2021;143:583);
  - consider DOAC only after 12 mos (JACC 2021;77:629)
- If concern for procedural bleed, interrupt OAC (1–2 d DOAC, 4–5 d VKA).
- If CHA2DS2-VASc ≥ _7_ (or ≥5 w/ h/o CVA/TIA),

  - consider bridge w/ UFH/LMWH,
  - otherwise do not (JACC 2017;69:735).

- [[Direct Oral Anticoagulants (DOACs) for NVAF]]
- [[Properties and Antidotes for Anticoagulants Fibrinolytics]]
